Skip to content
Review Open access

Decentralized CAR-T production: clinical, economic, and regulatory perspectives. Worldwide Network for Blood & Marrow Transplantation (WBMT) special article.

Sep 2026 · Bone Marrow Transplantation · 1 citation · 52 references
Medicine

TL;DR

This review summarizes the current landscape of POC CAR T-cell manufacturing, emphasizing clinical outcomes, economic sustainability, and regulatory considerations, and discusses emerging technologies, including allogeneic CAR T-cell platforms, artificial intelligence-driven manufacturing, and in vivo gene editing, that may democratize global access.

Read PDF

Similar papers

Review Open access Aug 2026

A proposal of good manufacturing practices (GMP) laboratory for CAR T-cell therapy in Latin America and the Caribbean: challenges and opportunities

This model advocates for decentralized, modular cleanroom facilities that integrate fully closed automated manufacturing platforms with risk-based quality management systems and emphasizes the strategic implementation of artificial intelligence (AI) and digital health tools—such as electronic batch records and predicti...

S. Cabrera-Salcedo, L. Parra-Lara, Mónica Fernandes-Pineda et al. · 0 citations
Review Open access Sep 2026

Next-generation CAR-T cell therapy against cancer: precision engineering, programmable immunity, and emerging clinical frontiers

While chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of hematological malignancies, there are significant hurdles to overcome, such as antigen escape, T-cell exhaustion, limited persistence in the body, severe toxicities, manufacturing complexity, high costs, and low effectiveness in...

Faizan-e-Mustaffa, Muhammad Shahbaz Aslam, Muhammad Junaid · 0 citations
Review Open access Sep 2026

[In vivo CAR-T cells: When the patient becomes their own factory].

The main delivery platforms under clinical investigation are described, focusing on lentiviral vectors and lipid nanoparticles, and their differences in terms of mechanisms of action, associated risks, and optimization strategies are discussed.

François Vilcot, Carole-Anne Brugère, Jaime Fuentealba et al. · 0 citations
Review Open access Aug 2026

In vivo CAR T cells on the highway: a roadmap for the next decade

Although still in its infancy, in vivo genetic engineering shows promise for CAR T cell therapy in a wide range of cancer patients and has the potential to reprogram patients’ immunity in autoimmunity, chronic infections, and regenerative medicine.

Markus Barden, D. Harrer, Hinrich Abken · 0 citations
Review Oct 2026

Toward the next generation of CAR T cell therapies for cancer.

The clinical lessons learned from the now substantial experience with commercial CAR T cells and clinical trials are summarized and three waves shaping next-generation development are discussed: multi-engineered and logic-gated CAR T cells, rational combination strategies, and in vivo CAR T cell generation.

D. Usta, Crystal L. Mackall · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.